lonvoguran ziclumeran (also referred to as NTLA-2002) — PDUFA
Mar 10
FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027Source filing
NTLA biotech catalysts & pipeline
INTELLIA THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
nexiguran ziclumeran (also referred to as NTLA-2001) — NDA/BLA submission
by 2028
Intellia anticipates submitting a biologics license application (BLA) for ATTRv-PN by 2028.Source filing